Baxter Int'l (BAX) Reports BAX 855 Met Primary Endpoint in Phase 3
Tweet Send to a Friend
Baxter Int'l (NYSE: BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
